Share on StockTwits

DexCom (NASDAQ:DXCM) CEO Terrance H. Gregg unloaded 56,107 shares of DexCom stock on the open market in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $43.57, for a total value of $2,444,581.99. Following the sale, the chief executive officer now directly owns 395,626 shares of the company’s stock, valued at approximately $17,237,425. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, August 8th. They now have a $46.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, August 7th. They now have a $46.00 price target on the stock, up previously from $44.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom from $40.00 to $48.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $41.00.

Shares of DexCom (NASDAQ:DXCM) opened at 43.62 on Monday. DexCom has a 1-year low of $25.49 and a 1-year high of $49.83. The stock’s 50-day moving average is $39.1 and its 200-day moving average is $38.74. The company’s market cap is $3.292 billion.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter last year, the company posted ($0.14) earnings per share. DexCom’s revenue was up 64.2% compared to the same quarter last year. Analysts expect that DexCom will post $-0.32 EPS for the current fiscal year.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.